Skip to content
- Manufacturable in volume, at speed
- Safe, effective, affordable
- New variant versions simple and rapid to produce
- Needle free. Overcomes needle phobia. More amenable for use with children
- More cost effective, no health care professional required to administer
- Effective Cross strain protective, valuable for seasonal changes in influenza and for pandemics
- Long-lasting protection
- No anti-vector reactivity
- T-Cell induction
- More boostable immune responses
- Lower dose is required, reducing costs and time of manufacture and facilitating storage and logistics issues
- No cold chain.
- Lower costs enable LMI Countries to be included immediately
- No lag time to bank feedstocks & manufacture vaccine lots
- Disease X ready
- More effective against SARS-CoV-2 and variants, Influenza, RSV, TB and more